Please login to the form below

Not currently logged in
Email:
Password:

David Noble to leave Edelman

David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure

David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure.

Noble has been heading the agency's specialist medical communications business unit for more than three years. He is to leave this month following a three-week consultation process.

Steve Spurr who leads Edleman's ethical healthcare division will take over Noble's responsibilities.

Robert Phillips, Edelman UK CEO told PR Week: "The BioScience and Rx divisions will remain separate, but will be headed by Steve. We are reorganising internally to have more fluent interaction between the teams."

The BioScience division specialises in advisory board management, clinical trial recruitment/retention, market access support, publication planning, meetings and symposia.

13th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics